Kymera Therapeutics (KYMR) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.

8 equities research analysts have issued twelve-month target prices for Kymera Therapeutics' shares. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they anticipate the company's stock price to reach $47.22 in the next year. This suggests a possible upside of 74.6% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.

Kymera Therapeutics' stock was trading at $24.96 at the beginning of the year. Since then, KYMR stock has increased by 8.4% and is now trading at $27.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our KYMR earnings forecast.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its earnings results on Thursday, May, 4th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.01. The firm had revenue of $9.47 million for the quarter, compared to analyst estimates of $14.15 million. Kymera Therapeutics had a negative net margin of 340.80% and a negative trailing twelve-month return on equity of 34.15%. The company's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned ($0.71) earnings per share.

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Simplify Propel Opportunities ETF (SURI), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

(KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Kymera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (10.59%), BVF Inc. IL (8.57%), Price T Rowe Associates Inc. MD (8.44%), Wellington Management Group LLP (7.76%), Avoro Capital Advisors LLC (6.97%) and BlackRock Inc. (6.02%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KYMR stock can currently be purchased for approximately $27.05.

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $1.50 billion and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.

The company employs 141 workers across the globe.

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.